Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MRNA vs IBRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MRNA Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

MRNA Overall Winner 6-Pillar Tally: MRNA 3 – 3 IBRX Matrix Metrics: MRNA 6 – 4 IBRX

As of Nov 20, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over ImmunityBio, Inc. (IBRX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas IBRX carries 61.4/100 (BUY) at $6.02 (60.2x Forward P/E, -150.2% operating margin).

  • Composite vs. Pillar Nuance: While IBRX currently prints a higher short-term Unified Composite Score (61.4/100 BUY vs. MRNA 40.3/100 SELL), MRNA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-80.8% vs. -150.2% operating margin) and revenue trajectory (+29.2% vs. +52.3% YoY).
  • Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile IBRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRNA vs IBRX
MRNA NASDAQ Head-to-Head Winner
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89
IBRX NASDAQ
ImmunityBio, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.02
-8.37% 1D
Market Cap $7.0B
TTM Revenue $183M
Forward P/E 60.2x
Beta / 30D Vol 1.68β · 107% Vol
Unified Composite Score
61.4 / 100 BUY
Tech 75.0 Fund 69.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.6%), weak momentum, RSI 36
RSI-14: 35.8 · SMA20: $7.41 · SMA50: $8.42

6-Pillar Scorecard Institutional Category Breakdown (MRNA 3 – 3 IBRX)

Columns: Metric · MRNA · IBRX
1. Valuation Multiples MRNA
Forward P/E 23.0x 60.2x
Trailing P/E 23.0x 60.2x
PEG Ratio N/M N/M
EV / Revenue 33.1x 42.8x
2. Growth & Scale IBRX
Revenue Growth (YoY) +29.2% +52.3%
Earnings Growth (YoY) -85.1% +0.0%
TTM Revenue (USD) $2.52B $183M
Market Cap $80.7B $7.0B
3. Profitability & Quality IBRX
Gross Margin -42.0% 98.8%
Operating Margin -80.8% -150.2%
Net Profit Margin -110.5% 0.0%
Return on Equity (ROE) -34.5% 0.0%
4. Balance Sheet & Cash Flow MRNA
Cash Generation (TTM) -$2.04B -$297M
Cash Flow Margin -81.0% N/A
Net Cash / Leverage $3.03B Net Debt (0.62x D/E) $824M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IBRX
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 89.6% (52nd %ile) 86.8% (14th %ile)
Put/Call OI Skew 1.05x (Balanced) 0.68x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 38.8% of Rev ($980M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRNA (6) vs IBRX (4)
Institutional Metric MRNA IBRX Criterion Row Edge
Market Capitalization
Scale
$80.7B $7.0B Larger Scale MRNA
Trailing P/E Ratio
Valuation
23.0x 60.2x Lower Multiple MRNA
Forward P/E Ratio
Valuation
23.0x 60.2x Lower Multiple MRNA
Revenue Growth (YoY)
Growth
+29.2% +52.3% Higher Growth IBRX
Operating Margin (TTM)
Profitability
-80.8% -150.2% Higher Margin MRNA
Net Profit Margin
Profitability
-110.5% 0.0% Higher Margin IBRX
Return on Equity (ROE)
Capital Efficiency
-34.5% 0.0% Higher ROE IBRX
52-Week Range Position
Momentum
67% ($22–$281) 39% ($2–$12) Stronger Trend MRNA
Beta / 30D Volatility
Risk Regime
2.23β · 78% Vol 1.68β · 107% Vol Lower Realized Risk MRNA
Unified Institutional Score
Composite Signal
40.3 / 100 (SELL) 61.4 / 100 (BUY) Higher Composite IBRX
Trailing 12M Revenue (USD)
Operating Scale
$2.52B $183M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.0% 98.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 33.1x EV/Rev N/M PEG · 42.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.04B ($3.03B Net Debt (0.62x D/E)) -$297M ($824M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MRNA +23.79 pp
MRNA: -3.77% · IBRX: -27.56%
3M Horizon MRNA +60.98 pp
MRNA: +40.4% · IBRX: -20.58%
6M Horizon MRNA +332.58 pp
MRNA: +315.96% · IBRX: -16.62%
1Y Horizon MRNA +525.14 pp
MRNA: +706.45% · IBRX: +181.31%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MRNA Revenue IBRX Revenue MRNA Op. Margin IBRX Op. Margin Margin Leader
FY2018 $140M $0M -306.0% -209338.3% MRNA
FY2019 $60M $0M -906.8% -7095.9% MRNA
FY2020 $800M $0M -95.0% -36509.1% MRNA
FY2021 $18.5B $0M 72.0% -35361.9% MRNA
FY2022 $19.3B $0M 48.9% -146374.2% MRNA
FY2023 $6.85B $0M -61.9% -58239.5% MRNA
FY2024 $3.24B $10M -121.9% -2334.2% MRNA
FY2025 $1.94B $110M -158.1% -226.0% MRNA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IBRX BREAKDOWN
30d in phase · OBV NEUTRAL
Current IV 86.8%
IV Percentile 14th %ile
Put/Call OI Skew 0.68x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA vs. IBRX: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of MRNA ($21,527) vs. IBRX ($661) against risk-defined 5-day vertical and put-wall option structures.

MRNA Spot $215.27 · IV 83.7%
MRNA Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
IBRX Spot $6.61 · IV 84.5%
IBRX Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $7 / $8 Bull Call Spread

Buy 4x $7C · Sell 4x $8C · 30d

Net Entry $100 Debit
T+5d @ +5% Move +$26 (+26%)
Max Risk / Buffer $100 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $7 / $6 Bear Put Spread

Buy 3x $7P · Sell 3x $6P · 30d

Net Entry $111 Debit
T+5d @ -5% Drop +$24 (+22%)
Max Risk / Buffer $111 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics
IBRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.0B market capitalization and -150.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MRNA vs IBRX Key Questions & Quantitative Answers

As of Nov 20, 2026, Moderna, Inc. (MRNA) is the stronger overall head-to-head candidate over ImmunityBio, Inc. (IBRX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas IBRX carries 61.4/100 (BUY) at $6.02 (60.2x Forward P/E, -150.2% operating margin). Composite vs. Pillar Nuance: While IBRX currently prints a higher short-term Unified Composite Score (61.4/100 BUY vs. MRNA 40.3/100 SELL), MRNA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-80.8% vs. -150.2% operating margin) and revenue trajectory (+29.2% vs. +52.3% YoY). Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile IBRX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IBRX leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with IBRX at +52.3% YoY revenue growth and +0.0% YoY earnings growth on $183M TTM revenue (98.8% gross margin, -150.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MRNA cumulative revenue shifted +1285.7% while IBRX shifted +1000.0%. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBRX.

MRNA screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas IBRX trades at 60.2x Forward P/E, 60.2x Trailing P/E, N/M PEG, and 42.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus IBRX (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, IBRX carries 86.8% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.68x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.68β · 107% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.